ImageneBio (NASDAQ:IMA) is now covered by analysts at Wedbush. They set an "underperform" rating and a $2.00 price target on the stock.
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team [Yahoo! Finance]
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences